EFFICACY OF JOSHANDA ZEEQUNNAFAS AND HABBE HINDI ZEEQI IN ZEEQUNNAFAS (BRONCHIAL ASTHMA) - AN OBSERVATIONAL OPEN CLINICAL TRIAL

Background: Bronchial asthma is a major public health concern, affecting 100-150 million people worldwide and accounts for an estimated 1,80,000 deaths per year. Its incidence is swiftly escalating in India. Unani medicine is augment with many single and compound drugs, which own potential effects to cure the disease, but these formulations are not proof scientifically. Objective: To evaluate the efficacy of Joshanda Zeequnnafas and Habbe Hindi Zeeqi in the treatment of Zeequnnafas to provide safe and effective treatment for asthma. Methods: The clinical trial to assess the efficacy of Joshanda Zeequnnafas and Habbe Hindi Zeeqi in the management of asthma. 50 patients were screened and out of them 30 patients were selected for study. Joshanda Zeequnnafas and Habbe Hindi Zeeqi were administered orally 50 ml (as decoction) twice a day and 125 mg (as tablet form) twice a day for 45 days. Subjective and objective parameters follow up before and after treatment on 0, 15 th , 30 th , and 45 th day of the treatment. In subjective parameter, paroxysmal dyspnoea and wheeze was analysed using paired proportion test. Objective parameter was assessed by the help of Spirometry in terms of ESR, Eosinophilia, FEV1, FEV1/FVC% and PEF and student paired t test was applied to get the results. Safety parameters included complete blood count, SGOT, SGPT, Blood urea, S. Creatinine, RBS, and Urine routine and microscopic; and were assessed on student paired t test. Results: The overall result was highly significant in terms of subjective and objective parameters specially FEV1and PEF (P 0.178, 0.785, and 0.220 respectively. Conclusion: The study results suggest that the trials formulations are quite effective in the management of Zeequnnafas. No adverse effects were noted during the complete course of the study trial. Hence it infers that trial drugs are safe, and effective in the treatment of Zeequnnafas (bronchial asthma).